Pulnovo Medical gibt Ergebnisse der PADN-HF-PH-Studie auf dem ESC-Kongress 2026 bekannt; diese werden gleichzeitig im „New England Journal of Medicine" (NEJM) veröffentlicht
Data ReadoutpositivePositive
AI Analysis
Summary
Pulnovo Medical announced positive results from the PADN-HF-PH study of 264 patients with pulmonary hypertension and left ventricular hypertrophy, showing a 51% reduction in clinical worsening risk and 35.5% reduction in recurrent events, published simultaneously at ESC Congress 2026 and in the New England Journal of Medicine.
Clinical Trial Data
Primary Endpoint
Met
Patients
264
Outcome Details
PADN-HF-PH study showed 51% reduction in risk of clinical worsening, 35.5% reduction in recurrent clinical events in 264 patients with PH-LHD
Importance:8/10
Sentiment:
0.80
Phase 3Data ReadoutPulmonary HypertensionESC Congress 2026NEJM Publication
Read the original article
Published by PR Newswire Pharma on September 3, 2026 7:37 PM